Palisade Bio (PALI) director gets 592,300 RSU grant and 20,200 RSUs vest
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Palisade Bio director Binxian Wei reported equity compensation activity involving restricted stock units (RSUs) and common shares. On June 10, 2026, Wei received a grant of 592,300 RSUs of Palisade Bio common stock at no cash cost.
The filing also shows 20,200 RSUs converting into the same number of common shares as they vested on June 10, 2026. One line reports 613,355 common shares held directly after the RSU vesting, and another reports 593,155 shares after the new RSU grant. The RSU awards are subject to service-based vesting over three annual installments tied to future stockholder meetings or specified anniversaries, so Wei must remain in service for full delivery of shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
20,200 shares exercised/converted
Mixed
3 txns
Insider
Wei Binxian
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 20,200 | $0.00 | -- |
| Grant/Award | Common Stock | 592,300 | $0.00 | -- |
| Exercise | Common Stock | 20,200 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 40,400 shares (Direct, null);
Common Stock — 593,155 shares (Direct, null)
Footnotes (1)
- The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.
Key Figures
RSUs granted: 592,300 RSUs
RSUs vested: 20,200 RSUs
Shares after vesting line: 613,355 shares
+4 more
7 metrics
RSUs granted
592,300 RSUs
Grant to director on June 10, 2026
RSUs vested
20,200 RSUs
Vested and converted into common stock on June 10, 2026
Shares after vesting line
613,355 shares
Common stock held directly following RSU vesting transaction
Shares after grant line
593,155 shares
Common stock held directly following RSU grant entry
Exercise price per share
$0.0000 per share
Reported for RSU-related common stock acquisitions
Exercise transactions
1 derivative exercise, 20,200 shares
transactionSummary exerciseCount and exerciseShares
Total acquire-type transactions
3 transactions
transactionSummary acquireCount
Key Terms
Restricted Stock Units, service-based vesting, annual installments, contingent right, +1 more
5 terms
Restricted Stock Units financial
"The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
service-based vesting financial
"The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments..."
annual installments financial
"The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments..."
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."
grant, award, or other acquisition regulatory
"transaction_code_description: Grant, award, or other acquisition"
FAQ
What did Palisade Bio (PALI) director Binxian Wei report in this Form 4?
Director Binxian Wei reported equity compensation transactions, including a grant of 592,300 restricted stock units and the vesting of 20,200 RSUs into common shares, all dated June 10, 2026, with no cash paid per share.
How many RSUs were granted to Palisade Bio (PALI) director Binxian Wei?
The Form 4 shows a grant of 592,300 restricted stock units to director Binxian Wei. Each RSU represents a contingent right to receive one share of Palisade Bio common stock, subject to service-based vesting conditions over multiple years.
What RSUs vested for Palisade Bio (PALI) director Binxian Wei on June 10, 2026?
20,200 previously granted RSUs vested on June 10, 2026, converting into 20,200 shares of Palisade Bio common stock. These RSUs were part of a service-based award that vests in three equal annual installments tied to continued service.
What are the vesting terms of Binxian Wei’s new RSU grant at Palisade Bio (PALI)?
The new RSU grant vests in three equal annual installments. The first installment vests on the earlier of the 2027 annual meeting of stockholders or the anniversary of June 10, 2026, conditioned on Wei’s continuous service with Palisade Bio.